1. Urotensin II activates sarcolemmal Na+/H+ exchanger in adult rat ventricular myocytes.

Kato K, et.al. J Cardiovasc Pharmacol. 2010 Feb;55(2):191-7

 

2. Comparison of nonculprit coronary plaque characteristics between patients with and without diabetes: a 3-vessel optical coherence tomography study.

Kato K, et.al. JACC Cardiovasc Interv. 2012 Nov;5(11):1150-8.

 

3. Nonculprit plaques in patients with acute coronary syndromes have more vulnerable features compared with those with non-acute coronary syndromes: a 3-vessel optical coherence tomography study.

Kato K, et.al. Circ Cardiovasc Imaging. 2012 Jul;5(4):433-40

 

4. Nonculprit coronary plaque characteristics of chronic kidney disease.

Kato K, et.al. Circ Cardiovasc Imaging. 2013 May 1;6(3):448-56.

 

5. Intracoronary imaging modalities for vulnerable plaques.

Kato K, et.al. J Nippon Med Sch. 2011;78(6):340-51. 

 

6. Marked improvement of extensive atelectasis by unilateral application of the RTX respirator in elderly patients.

Kato K, et.al. Intern Med. 2009;48(16):1419-23.

 

7. Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization.

Kato K, et.al. Circ J. 2008 Sep;72(9):1499-505.

 

8. Mixed angina pectoris.

Kato K, Yasutake M. Nihon Rinsho. 2007 Sep 28;Suppl 5 Pt 2:117-20.

 

9. Combined therapy with percutaneous coronary intervention and percutaneous aortic valvuloplasty under mechanical support for an elderly patient with cardiogenic shock.

Kato K, et.al. J Nippon Med Sch. 2006 Jun;73(3):158-63.

 

10. Initial experiences of removal of intra-aortic balloon pumps with the Angio-Seal.

Kato K, et.al. J Invasive Cardiol. 2006 Mar;18(3):130-2.

 

11. Impact of Brain Natriuretic Peptide, Calcium Channel Blockers, and Body Mass Index on Recovery Time from Left Ventricular Systolic Dysfunction in Patients With Takotsubo Cardiomyopathy.

Shiomura　R, Kato K, et al.　Am J Cardiol. 2015 Aug 15;116(4):515-9.

 

12. Target lesion evaluation by multiple modalities in vivo: near-infrared spectroscopy (NIRS), virtual histology intravascular ultrasound, optical coherence tomography, and angioscopy.

Shibuya J, Kato K, et.al. EuroIntervention. 2015 Oct;11(6)

 

13. Superiority of the extracellular volume fraction over the myocardial T1 value for the assessment of myocardial fibrosis in patients with non-ischemic cardiomyopathy.

Inui K, Kato K, et.al. Magn Reson Imaging. 2016 Oct;34(8):1141-5

 

14. Plaque Characteristics in Coronary Artery Disease Patients with Impaired Glucose Tolerance.

Suzuki K, Kato K, et.al. PLoS One. 2016 Dec 9;11(12):0167645

 

15. Comparison by optical coherence tomography of the frequency of lipid coronary plaques in current smokers, former smokers, and nonsmokers.

Abtahian F, Kato K, et.al. Am J Cardiol. 2014 Sep 1;114(5):674-80.

 

16. Residual thrombus pattern in patients with ST-segment elevation myocardial infarction caused by plaque erosion versus plaque rupture after successful fibrinolysis: an optical coherence tomography study.

Hu S, Kato K, et.al. J Am Coll Cardiol. 2014 Apr 8;63(13):1336-8.

 

17. Comprehensive overview of definitions for optical coherence tomography-based plaque and stent analyses.

Di Vito L, Kato K, et.al. Coron Artery Dis. 2014 Mar;25(2):172-85.

 

18. Pancoronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: a 3-vessel optical coherence tomography study.

Vergallo R, Kato K, et.al. Am Heart J. 2014 Jan;167(1):59-67. 

 

19. Comparison of near-infrared spectroscopy and optical coherence tomography for detection of lipid.

Yonetsu T, Kato K, et.al. Catheter Cardiovasc Interv. 2014 Nov 1;84(5):710-7.

 

20. Correlation between degree of neointimal hyperplasia and incidence and characteristics of neoatherosclerosis as assessed by optical coherence tomography.

Vergallo R, Kato K, et.al.  Am J Cardiol. 2013 Nov 1;112(9):1315-21.

 

21. Features of coronary plaque in patients with metabolic syndrome and diabetes mellitus assessed by 3-vessel optical coherence tomography.

Yonetsu T, Kato K, et.al. Circ Cardiovasc Imaging. 2013 Sep;6(5):665-73.

 

22. Optical coherence tomography– 15 years in cardiology.

Yonetsu T, Kato K, et.al. Circ J. 2013;77(8):1933-40. 

 

23. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography.

Jia H, Kato K, et.al. J Am Coll Cardiol. 2013 Nov 5;62(19):1748-58.

 

24. Comparison of zotarolimus-eluting stent and everolimus-eluting stent for vascular healing response: serial 3-month and 12-month optical coherence tomography study. Kim SJ, Kato K, et.al. Coron Artery Dis. 2013 Aug;24(5):431-9.

 

25. Ticagrelor immediately prior to stenting is associated with smaller residual thrombus in patients with acute coronary syndrome.

Abtahian F, Kato K, et.al. Int J Cardiol. 2013 Oct 3;168(3):3099-101.

 

26. Evaluation of culprit lesions by optical coherence tomography in patients with ST-elevation myocardial infarction.

Vergallo R, Kato K, et.al. Int J Cardiol. 2013 Sep 30;168(2):1592-3. 

 

27. Lipid rich plaque, female gender and proximal coronary stent edge dissections.

Zeglin-Sawczuk M, Kato K, et.al. J Thromb Thrombolysis. 2013;36(4):507-13. 

 

28. In vivo comparison of lumen dimensions measured by time domain-, and frequency domain-optical coherence tomography, and intravascular ultrasound.

Kim SJ, Kato K, et.al. Int J Cardiovasc Imaging. 2013 Jun;29(5):967-75. 

 

29. Clinical backgrounds and the time course of sleep-disordered breathing in patients after myocardial infarction.

Hayashi H, Kato K, et.al. J Nippon Med Sch. 2013;80(3):192-9

 

30. Reversible stenosis of the saphenous vein graft compressed by giant coronary aneurysm in Kawasaki disease.

Hosokawa Y, Kato K, et.al. J Am Coll Cardiol. 2013 Jul 9;62(2):e3. 

 

31. Prognostic value of depression, anxiety, and anger in hospitalized cardiovascular disease patients for predicting adverse cardiac outcomes.

Nakamura S, Kato K, et.al. Am J Cardiol. 2013 May 15;111(10):1432-6.

 

32. Reproducibility of in vivo measurements for fibrous cap thickness and lipid arc by OCT. Kim SJ, Kato K, et.al. JACC Cardiovasc Imaging. 2012 Oct;5(10):1072-4.

 

33. Significance of intraplaque neovascularisation for vulnerability: optical coherence tomography study.

Tian J, Kato K, et.al. Heart. 2012 Oct;98(20):1504-9. 

 

34. Predictors for neoatherosclerosis: a retrospective observational study from the optical coherence tomography registry.

Yonetsu T, Kato K, et.al. Circ Cardiovasc Imaging. 2012 Sep 1;5(5):660-6.

 

35. Comparison of incidence and time course of neoatherosclerosis between bare metal stents and drug-eluting stents using optical coherence tomography.

Yonetsu T, Kato K, et.al. Am J Cardiol. 2012 Oct 1;110(7):933-9.

 

36. Does neovascularization predict response to statin therapy? Optical coherence tomography study.

Tian J, Kato K, et.al.　Int J Cardiol. 2012 Jul 26;158(3):469-70

 

37. Disruption of atherosclerotic neointima seven years after bare metal stent deployment.

Inami S, Kato K, et.al. Int Heart J. 2012;53(4):261-2.

 

38. Effect of long-term nitrate treatment on cardiac events in patients with vasospastic angina.

Kosugi M, Kato K, et.al. Circ J. 2011;75(9):2196-205. 

 

39. Angioscopic study of silent plaque disruption in nonischemic related coronary artery in patients with stable ischemic heart disease.

Wang Z, Kato K, et.al. Int Heart J 2010;51(6)383-7

 

40. Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure.

Tanaka K, Kato K, et.al. J Cardiol. 2010 Nov;56(3):291-9.

 

41. Solutions for retention of female cardiologists: from the survey of gender differences in the work and life of cardiologists.

Tsukada YT, Kato K, et.al.Circ J.2009;73(11):2076-83

 

42. Thrombolysis with a novel modified tissue-type plasminogen activator, monteplase, combined with catheter-based treatment for major pulmonary embolism.

Yamamoto T, Kato K, et.al. Circ J. 2009 Jan;73(1):106-10. 

 

43. Inappropriate analyses of automated external defibrillators used during in-hospital ventricular fibrillation.

Yamamoto T, Kato K, et.al. Circ J. 2008 Apr;72(4):679-81

 

44. Coronary perforation during percutaneous coronary intervention.

Shirakabe A, Kato K, et.al. Int Heart J. 2007 Jan;48(1):1-9.

 

45. Transient leukocytopenia associated with a steep surge of pro-inflammatory cytokines in a patient with severe cardiogenic pulmonary edema.

Yamamoto T, Kato K, et.al. Intern Med. 2006;45(20):1153-5.

 

46. Plaque Characteristics in Coronary Artery Disease Patients with Impaired Glucose Tolerance.Suzuki K, Kato K, et.al. PLos One. 2016;11(12):e00617-645

 

47. Superiority of the extracellular volume fraction over the myocardial T1 value for the assessment of myocardial fibrosis in patients with non-ischemic cardiomyopathy.

Inui K, Kato K, et.al. Magn Reson Imaging. 2016;34(8)1141-5

 

48. Impact of Brain Natriuretic Peptide, Calcium Channel Blockers, and Body Mass Index on Recovery Time from Left Ventricular Systolic Dysfunction in Patients WithTakotsubo Cardiomyopathy.

Shiomura R, Kato K, et.al. Am J Cardiol. 2015;116(4)515-9

 

49. Target lesion evaluation by multiple modalities in vivo: near-infrared spectroscopy (NIRS), virtual histology intravascular ultrasound, optical coherence tomography, and angioscopy.

Shibuya J, Kato K et.al. EuroIntervention 2015;11(6)